• Lyvgen Biopharma Presents Clinical Trial Data of CD137/4-1BB Agonistic Antibody LVGN6051 at the 2021 ASCO Annual Meeting

     

     

    June 4, 2021

     

    Lvgen Biopharma, a biotech company focused on developing innovative immuno-oncology therapeutics, announces that it will present a Trials in Progress poster presentation at the American Society of Clinical Oncology Annual Meeting (ASCO), to be held in a virtual format from June 4 to 8, 2021.

    The Trials in Progress poster presentation summarizes the safety profile, antitumor activity observed in a phase I clinical trial (NCT04130542) in collaboration with Merck & Co., Inc., Kenilworth, New Jersey, U.S.A., known as MSD outside of the U.S. and Canada. The trial is evaluating LVGN6051, a second generation 4-1BB (CD137) agonist antibody based on Lyvgen proprietary xLinkAb platform, as monotherapy or in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in adult patients with advanced malignancies. No MTD was reached at 7 mg/kg monotherapy and 4 mg/kg q3w monotherapy was determined as RP2D. Preliminary antitumor activity in late stage cancer patients was observed. Combination with pembrolizumab induced rapid antitumor responses in advanced cancer patients with immune-cold tumor or relapsed from prior immunotherapies.

     

    Presentation Details:

    Abstract title: Early safety and efficacy from a phase I open-label clinical trial of CD137 (4-1BB) agonistic antibody LVGN6051 as monotherapy and in combination with pembrolizumab.
    Abstract number: 2521
    Poster Session: Developmental Therapeutics—Immunotherapy
    The 2021 ASCO Annual Meeting will take place virtually on June 4 – 8, 2021 via the ASCO website, https://meetings.asco.org/

     

    KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
     

    About LVGN6051
    LVGN6051 is xLinkAb anti-4-1BB (CD137) agonist mAb that has been designed to activate 4-1BB optimally in tumor microenvironment by targeting both 4-1BB and FcγRIIB. LVGN6051 strikes a balance between antitumor efficacy and safety by agonizing 4-1BB only in the presence of FcγRIIB, which is expressed on immune cells enriched in the tumor microenvironment, including B cells, dendritic cells and granulocytes.

    About Lyvgen
    Lyvgen is an innovative biotech company focused on developing novel therapies for cancer. Its proprietary xLinkAb functional platform generated agonistic antibodies with tumor-localized immunostimulatory activities by balancing multiple functions of candidate antibodies, which has helped to generate a number of drug candidates, including LVGN7409 (CD40 agonist mAb) and LVGN6051 (4-1BB agonist mAb), presently in clinical development. Lyvgen employs over 60 scientists with global pharmaceutical research and development experience at its discovery, CMC and clinical operational sites in China and the USA.

    For more information, visit www.lyvgen.com

     

    Contact
    Janice Marie McCourt, RPH, MBA, CLP
    Mobile (USA): 617-470-3992
    janicemarie.mccourt@lyvgen.com

    Luyan Liu, Ph.D
    Mobile (China): 17721140552
    Luyan.liu@lyvgen.com

     

    Related news in the Media

    businesswire Lyvgen Biopharma Presents Clinical Trial Data of CD137/4-1BB Agonistic Antibody LVGN6051 at the 2021 ASCO Annual Meeting